EPC-TM net represents a unique mix of people with different skills all dedicated towards a better understanding of the impact of different components of the tumour microenvironment on pancreatic cancer tumour progression. This team is drawn from different EU member states, cultures and backgrounds but all working together towards a common goal.
The coordinator of the EPC-TM net project is Prof. Dr. Thomas Gress from Philipps-Universität-Marburg (UNIMAR), Germany.
The consortium has been specifically designed to include all required levels of expertise:
- surgical and medical oncology groups conducting the largest clinical trials for pancreatic cancer in Europe,
- expert pancreatic pathologists,
- basic scientists focused on the study of carcinogenesis and tumour microenvironment interactions in the pancreas,
- molecular oncology groups that have developed genetically engineered mouse models faithfully recapitulating human pancreatic cancer, as well as
- pharmaceutical industry specialised on drug development.
|Philipps-University of Marburg||UNIMAR||Germany|
|The University of Liverpool||ULIV||United Kingdom|
|Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III||CNIO||Spain|
|Universitá degli studi di Verona||UNIVR||Italy|
|Axcentua Pharmaceuticals Limited||Axcentua||Sweden|
|Klinikum Rechts der Isar der Technischen Universität München||TUM-MED||Germany|
|Bayer Schering Pharma AG||BSP||Germany|
|Cancer Research UK||CR-UK||United Kingdom|
|Lab21 Limited||Lab21||United Kingdom|
|Fondazione Centro San Raffaele del Monte Tabor||HSR||Italy|
|Universitá degli studi di Torino||CeRMS-UniTO||Italy|
|NatiMab Therapeutics SRL||NatiMab||Italy|
|concentris research management GmbH||concentris||Germany|